Safety and Efficacy of Osimertinib in Treating an EGFR-Mutant Lung Cancer Patient with a Germline EGFR T790M Mutation

被引：0

作者：

Ma, W. ^{[1
]}

Gong, J. ^{[1
]}

Shan, J. ^{[2
]}

Lewis, D. ^{[2
]}

Xiao, W. ^{[3
]}

Hung, J. ^{[4
]}

Moore, E. H. ^{[5
]}

Zhang, Y. ^{[6
]}

Mans, N. Z. ^{[7
]}

Welborn, J. ^{[5
]}

Lam, K. S. ^{[3
]}

Li, T. ^{[1
]}

机构：

[1] Univ Calif Davis, Ctr Comprehens Canc, Div Hematol & Oncol, Sacramento, CA 95817 USA

[2] Albert Einstein Coll Med, Dept Genet, New York, NY USA

[3] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA

[4] Sierra Nevada Med Grp, Grass Valley, CA USA

[5] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA

[6] Univ Calif Davis, Sch Med, Dept Pathol & Lab Med, Sacramento, CA 95817 USA

[7] Univ Calif Davis, Hereditary Canc Program, Ctr Comprehens Canc, Sacramento, CA 95817 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

osimertinib; lung cancer; Germline EGFR T790M;

D O I：

10.1016/j.jtho.2017.09.590

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA 15.08

引用

页码：S1863 / S1864

页数：2

共 50 条

[1] Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer
Lee, Youngjoo
Lee, Geon Kook
Hwang, Jung-Ah
Yun, Tak
Kim, Heung Tae
Lee, Jin Soo
CLINICAL LUNG CANCER, 2015, 16 (01) : 46 - 50
[2] Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer
Ichihara, Eiki
Lovly, Christine M.
CANCER DISCOVERY, 2015, 5 (07) : 694 - 696
[3] Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations
Ma, Weijie
Gong, Jay
Shan, Jidong
Lewis, Debbie
Xiao, Wenwu
Moore, Elizabeth H.
Zhang, Yanhong
Hung, Jamie
Mans, Nicole Z.
Wei, Sixi
Welborn, Jenna
Stollenwerk, Nicholas S.
Lam, Kit S.
Li, Tianhong
JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 7
[4] Genomic Evolution in a Patient With Lung Adenocarcinoma With a Germline EGFR T790M Mutation
Maekinen, Netta
Zhou, Meng
Bemus, Meredith
Nevin, Julius
Nag, Anwesha
Chen, Ruthia
Colson, Yolonda L.
Thorner, Aaron R.
Oxnard, Geoffrey R.
Meyerson, Matthew
Sholl, Lynette M.
JTO CLINICAL AND RESEARCH REPORTS, 2021, 2 (04):
[5] Osimertinib Benefit in ctDNA T790M Positive, EGFR-Mutant NSCLC Patients
Remon, Jordi
Caramella, Caroline
Joelet, Cecile
Lacroix, Ludovic
Lawson, Andrew
Smalley, Sarah
Howarth, Karen
Gale, Davina
Rosenfeld, Nitzan
Green, Emma
Plagnol, Vincent
Planchard, David
Bluthgen, Maria
Gazzah, Annas
Pannet, Chloe
Nicotra, Claudio
Soria, Jean-Charles
Besse, Benjamin
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1254 - S1255
[6] Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?
Facchinetti, F.
Leonetti, A.
Tiseo, M.
ANNALS OF ONCOLOGY, 2020, 31 (11) : 1581 - 1582
[7] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
Gao, Xin
Le, Xiuning
Costa, Daniel B.
EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
[8] Monitoring of EGFR Mutations During Osimertinib Treatment in Advance EGFR-Mutant T790M Positive NSCLC
Mohorcic, K.
Janzic, A.
Janzic, U.
Rot, M.
Kern, I.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S557 - S558
[9] Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors
Dogan, Izzet
Khanmammadov, Nijat
Paksoy, Nail
Vatansever, Sezai
Saip, Pinar
Aydiner, Adnan
EURASIAN JOURNAL OF PULMONOLOGY, 2023, 25 (01) : 27 - 32
[10] Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
Buzard, Blake
Douglass, Lindsey
Gustafson, Beth
Buckley, Jennifer
Roth, Marc
Kujtan, Lara
Bansal, Dhruv
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (10) : 1829 - 1834

← 1 2 3 4 5 →